My thought is that this downgrade is due to factors analyst cited. Substantial increase in market cap with concern that leronlimab will not have anticipated efficacy. If one has doubts about the trial outcomes and does not recognize potential in Cancer and the myriad other indications, then his analysis would be appropriate.

We here feel very, very differently about the science behind leronlimab and its mechanism.

Seeing the downgrade this morning started my day with a hearty chuckle.